1.871USD+13.38%Mkt Cap: 214.03M USDP/E: —Last update: 2026-06-01
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to pr…
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap214.03M USD
Enterprise Value197.81M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-20.85M USD
Revenue/Share—
Last Price1.871 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.27
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B160.00
EPS (TTM)-12.70
EPS (Forward)-1.39
52W Range
0.92005% of range19.91
52W High19.91 USD
52W Low0.9200 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-661.54%
ROA-223.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.82M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-5.03%
Net Debt-1.50M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio2.34
Quick Ratio1.60
Book Value/Sh0.0110 USD
Cash/Share0.0130 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateOct 30, 2020
Splits
Last Split1:28
Split DateJun 27, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.113.24M
Float3.24M
Insiders0.74%
Institutions0.08%
Short Interest
Short Ratio1.1d
Short % Float0.05%
Short % Out.0.05%
Shares Short60.12K
Short (prev mo.)52.56K
Technical
SMA 502.080 (-10.1%)
SMA 2002.837 (-34.1%)
Beta1.39
S&P 52W Chg27.94%
Avg Vol (30d)78.38K
Avg Vol (10d)123.08K
Technical Indicators
RSI (14)46.6
MACD-0.2798
MACD Signal-0.2782
MACD Hist.-0.0016
BB Upper2.351 USD
BB Middle1.634 USD
BB Lower0.9165 USD
BB Width87.81%
ATR (14)0.2530 USD
Vol Ratio (20d)0.37x